As previously reported, BofA initiated coverage of Amphastar with a Neutral rating and $63 price target. While saying that Amphastar is “winning on two fronts,” specifically its core generic drug business and its acquisition of Baqsimi for diabetics, investors have driven the stock up 97% year-to-date so the firm thinks the current multiple already reflects Baqsimi-driven growth and the company’s pipeline. Given the high valuation relative to traditional generic peers, BofA sees a more balanced risk/reward.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMPH: